课题基金 / 基金详情

ACTIVE IMMUNOTHERAPY TO HUMAN CARCINOMA ASSOCIATED ANTIGENS

ACTIVE IMMUNOTHERAPY TO HUMAN CARCINOMA ASSOCIATED ANTIGENS
针对人类癌相关抗原的主动免疫治疗
批准号:
3808563
负责人:
J KANTOR
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

J KANTOR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Carcinoembryonic antigen (CEA) is a 180,000-dalton glycoprotein expressed on most gastrointestinal carcinomas and many other human carcinoma types. A 2.4-kb cDNA clone, containing the complete coding sequence, was isolated from a human colon tumor cell library and inserted into a vaccinia virus genome. This newly developed construct was characterized by Southern blotting, DNA hybridization studies and polymerase chain reaction analysis. The CEA gene was stably integrated in the vaccinia virus thymidine kinase gene. The recombinant was efficiently replicated upon serial passages in cell cultures and in animals. The recombinant virus expresses, on the surface of infected cells, a protein product recognized by a monoclonal antibody (COL-1) directed against CEA. Immunization of mice with the vaccinia construct was found to elicit a humoral immune response against CEA. Pilot studies also demonstrated that the administration of the recombinant CEA vaccinia construct was able to greatly reduce the growth in mice of a syngenic murine colon adenocarcinoma which had been transduced with the human CEA gene. The use of this new recombinant CEA vaccinia construct may thus provide an approach in the specific active immunotherapy of human gastrointestinal cancer and other CEA expressing carcinoma types.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISOLATION AND CHARACTERIZATION OF GENES CODING FOR CARCINOMA-ASSOCIATED ANTIGENS
DESIGN OF LIVE RECOMBINANT VACCINES FOR ACTIVE SPECIFIC IMMUNOTHERAPY
ACTIVE IMMUNOTHERAPY TO HUMAN CARCINOMA ASSOCIATED ANTIGENS
DESIGN OF LIVE RECOMBINANT VACCINES FOR ACTIVE SPECIFIC IMMUNOTHERAPY
海外基金